How to accept a loaned medical device before clinical use

A loan, demonstration or replacement device can arrive quickly and look familiar, but that does not make it ready for a patient. Before first clinical use, the provider needs to know what was supplied, whether it suits the task, who owns checks and maintenance, whether it is clean, whether users can operate it safely and where it will go after the loan.

Why a loan device needs a formal entry point

A sales representative offers a trial unit, a manufacturer supplies temporary cover while a hospital device is repaired, or another organisation lends a specialist device for one patient. The equipment may arrive quickly and look familiar. That does not mean it is ready for clinical use. The receiving provider needs to know what was supplied, whether it suits the intended task, who owns checks and maintenance, whether the device is clean, whether users can operate it safely and where it will go after the loan.

The MHRA Managing Medical Devices guidance addresses medical device management in hospitals and community organisations. Its section on devices loaned by manufacturers says they should have a written agreement defining management requirements, responsibilities and liabilities, including decontamination where relevant. Delivery receipt and pre-use procedures should be the same as for a purchased device unless the agreement specifies otherwise. This is a stronger test than signing a delivery note. The first clinical use should follow an acceptance decision that names the device, setting and user group.

The decision has several parts. Procurement or the sponsoring department confirms why the loan is needed and its terms. Clinical engineering or another competent technical service checks the device and its configuration. Infection prevention confirms any applicable cleaning and decontamination route. Clinical leaders confirm that the intended use and patient pathway are appropriate. Users receive the current instructions and necessary training. A person is appointed to keep the device traceable, maintained and recalled when the loan ends or a safety notice arrives. A central record helps, but it cannot replace those judgements.

Define the loan before delivery

Record who owns the device and who is authorised to provide it. Distinguish a manufacturer loan from a loan by another healthcare organisation, a rental, a demonstration and a device supplied for a clinical investigation. Each may have different terms and risk. A demonstration unit may have a history of use at several sites. A replacement unit may arrive already configured for another customer. A device supplied for a trial may require research governance beyond ordinary clinical acceptance. The local owner should establish the route before the unit enters a patient area.

A written agreement should identify the manufacturer or lender, model and device identifiers, start and planned end dates, intended clinical purpose, where it may be used, who is responsible for installation, maintenance, consumables, software updates, safety notices, insurance or liability, decontamination and return. It should say who provides training and current instructions, who can modify settings and how faults are reported. The MHRA full guidance explicitly calls for management responsibilities and liabilities to be defined for manufacturer loans. The provider’s legal and procurement team may need to review unusual terms.

Avoid accepting a vague promise that “the supplier will look after it”. Who performs a pre-use test if delivery occurs on a weekend? Who replaces a failed part? Can the supplier retrieve the device while it is supporting a patient? Who preserves configuration and patient data before return? Who cleans the device and declares its contamination status? The agreement should answer the questions that will matter during a fault or recall. If it cannot, do not send the unit straight to a ward and expect staff to improvise.

The clinical purpose also needs limits. A unit may be suitable for one type of monitoring but not another. Accessories, probes, software, power supply and consumables must be compatible. The receiving clinical lead should specify the intended patient group and use environment. An item that works in an outpatient room may not be appropriate in an intensive care area without further assessment. If a device is used outside the manufacturer’s intended purpose, the risks and responsibilities change. The MHRA warns that modifying a device or using it off-label has safety implications and may shift liability.

Receive and identify the exact device

On arrival, compare the delivered item with the agreement and clinical request. Record model, serial number, software version, accessories, consumables, manuals, power supply, packaging and condition. Verify that the device was not damaged in transit and that all components are present. If the item is sterile or supplied with a sterile accessory, check packaging integrity, expiry and storage conditions. A purchasing description alone may not prove that the correct configuration arrived.

The MHRA guidance on acceptance checks says organisations should compare newly delivered devices with the purchase or tender specification and carry out appropriate receipt and pre-use checks. Loaned manufacturer devices follow that same acceptance route unless the written agreement states otherwise. Acceptance tests should stay within normal-use bounds, not become destructive type testing. The technical team should follow the manufacturer and the organisation’s device policy for electrical, mechanical, performance and configuration checks where applicable.

Add the loaned device to the temporary inventory before release. The record should include ownership, location, user department, unique identifiers, intended use, acceptance status, service and safety notice contact, next review and return date. Use a visible label or other local means to distinguish it from owned equipment where necessary. If the unit moves between sites, update the record. A device that cannot be found cannot reliably receive a field safety notice or be returned at the end of the loan.

Do not confuse delivery receipt with acceptance. A porter may sign that a box arrived. A technical or clinical owner must determine whether the actual device may be used. Keep those signatures or electronic decisions separate. When a loan arrives urgently for a patient, an accelerated process may be necessary, but the safety questions do not vanish. Record who authorised the expedited checks and what limits apply until the full evidence is available.

Check decontamination and infection risk

A reusable medical device may carry contamination from a previous user or site. The provider needs evidence of its incoming decontamination status and a validated way to clean or reprocess it after use. The Health and Social Care Act 2008 code of practice on infection prevention explains that effective decontamination of reusable devices is central to infection risk control. It calls for traceability of invasive reusable instruments through the decontamination cycle and use in accordance with manufacturer instructions and relevant best practice.

Before acceptance, ask what patient contact the device has, which surfaces and accessories need cleaning, whether the lender supplied a decontamination declaration and whether the receiving site can carry out the manufacturer’s process. A device that requires a sterilisation method the site cannot provide may not be suitable for loan. A device with damaged surfaces or inaccessible contamination traps may be unsafe to share even if its electronic functions pass. Involve infection prevention and decontamination specialists for higher-risk items.

The MHRA guidance says decontamination needs should be considered before reusable devices are acquired. It also says that when a device is sent for repair or returned, a contamination status declaration should accompany it after appropriate decontamination. Include this in the loan agreement and return plan. A courier should not be asked to take a used device whose cleaning status is unknown. Staff carrying out cleaning need the right instructions, materials and protection.

Decontamination is not the only infection question. Where will the device be stored between patients? Are single-patient accessories truly single-patient, and who supplies replacements? Will it move between high-risk units? Can cables, touch screens, wheels and cases be cleaned under local procedures? If a specialist device is loaned to a patient at home, clarify who teaches cleaning and who inspects it on return. Avoid using a generic “clean on arrival” checkbox for equipment whose manufacturer requires a validated process.

Confirm configuration, compatibility and safe function

The technical team should check the configuration against the clinical need. That includes software version, alarm limits, measurement units, language, network settings, accessory compatibility, calibration and any patient data or prior-user information left on the device. The MHRA guidance recommends standard configuration sets signed by a lead clinician and verification of configuration before service. A loan unit that looks identical to an owned model may have different default settings or firmware.

If the device connects to a hospital network or exchanges patient information, information governance and cyber teams should review the connection. Confirm data flow, access, patching, supplier remote support and what happens to patient information at return. The device acceptance record can note that approval was granted without storing confidential network credentials or patient data in a general compliance system. A disconnected demonstration unit may still hold logs or test results from a previous site, so clearing them should be done under controlled instructions.

Check current safety communications. An incoming unit may be subject to a manufacturer field safety notice, or FSN, or MHRA Device Safety Information. Search using its exact model and serial or software version. Do not assume the lender has already implemented every correction. If a notice applies, record the action and evidence before release or follow the specified interim control. The wider process of finding and correcting affected devices across a provider’s inventory is covered in the related field safety notice response guide. Loan acceptance is the entry point where those checks should first become visible.

A local pre-use test should answer whether the device performs the required function under its intended conditions. It should not be a superficial power-on test if the clinical task depends on sensors, alarms, therapy settings or a specific accessory. Equally, a test must not exceed what the manufacturer allows. The competent service should define the acceptance result and any limits on use. If the unit fails, quarantine it, tell the lender and clinical department, and do not use it merely because the original device is unavailable.

Train the actual users, including cover staff

Users need access to the current instructions and an explanation of how this model differs from equipment they already know. The MHRA training section asks organisations to consider all anticipated users, carers, maintenance and decontamination staff. It specifically raises agency, on-call and locum staff, compatibility, contraindications, alarms, troubleshooting and reporting of device incidents. A representative demonstrating the device to one daytime clinician does not train every person who may use it overnight.

Agree the training method before first use. Some devices require a formal competence assessment, while others may need a focused briefing on configuration changes and safe operation. Record who was trained, by whom, on which version and when. Provide a route for staff joining later. Make instructions available where the device is used, including quick actions for faults and emergency substitution. If the manufacturer updates software or instructions during the loan, review the training content again.

A clinical lead should decide who is authorised to use the loan device and under what limits. Avoid a green status based solely on a generic course completion. A trained user also needs to understand this exact device and its accessories. If a loan device will be used in several departments, each service may need its own setup and handover. The training record should follow the users and device configuration, not just the loan contract.

Decide on clinical release with named owners

The release record should state that the loan agreement is in place, the delivered device matches the intended specification, the technical and infection checks passed, relevant safety notices were reviewed, required training is complete and the clinical use is approved. Record any restrictions, such as a specific ward, procedure, accessory or supervision requirement. A named clinical owner should accept the device for the intended patient pathway. A technical acceptance alone does not establish clinical suitability.

When a unit is urgently needed, record a time-limited conditional release only if local governance permits it and the competent decision-makers understand the residual risk. State which checks are complete, which remain open, who must supervise use and when the condition will be reviewed. Do not treat “urgent” as an exemption from decontamination or basic safety checks. If critical information is missing, the provider may need another clinical arrangement rather than a device with unknown history.

During the loan, maintain the device as agreed. Check servicing and calibration due dates, faults, safety notices, location changes and user training. The lender may own repairs, but the provider must know when a device is unavailable or unsafe. Record every service visit and changes to configuration. If the device is moved between departments, update the location and handover. If a patient-held device is transferred to another person, reissue and decontamination controls matter.

Return, transfer or extend without losing traceability

Plan the end before it arrives. Confirm the clinical service no longer needs the device, that alternatives are available and that any patient data have been handled under the agreement. Decontaminate and document the contamination status. Reconcile all accessories and consumables. Check that the lender receives the correct serial number and that the return is acknowledged. Close the inventory entry only after physical return or an authorised transfer is evidenced.

An extended loan needs a new review of terms, maintenance and training. A short demonstration can quietly become permanent equipment if nobody owns the date. Ask whether the device’s service contract, software support, conformity information and replacement plan still meet the provider’s needs. A long-running loan may make clinical teams dependent on a unit the lender can retrieve. The provider should make that risk visible to procurement and clinical management.

If the device is transferred to another provider rather than returned, confirm whether the agreement allows it and pass on the current instructions, service history, decontamination status and safety notice information. The receiving provider must perform its own acceptance decision. The first site’s approval is not a universal certificate for every setting. Update the traceability record so future recalls and field safety notices can reach the current holder.

Worked example: a temporary infusion pump

A hospital receives two manufacturer loan infusion pumps while its own pumps are repaired. The agreement identifies serial numbers, duration, maintenance support, decontamination responsibilities and recall contact. On delivery, clinical engineering checks condition, software version, calibration and compatible giving sets. The unit’s alarm settings differ from the hospital’s standard configuration. The lead clinician approves an aligned configuration and a pre-use check. Infection prevention verifies that the incoming units have an appropriate cleaning declaration and that the hospital can clean them between patients.

The ward lead arranges model-specific training for day and night staff, including agency cover, before first use. Both pumps are added to a temporary inventory and labelled with the owning service and return date. One pump later receives a manufacturer software notice, so its serial number is matched and the specified correction completed. At the end of the loan, each pump is cleaned, patient data handled under policy, accessories reconciled and return acknowledged. A delivery signature alone would not have provided any of those controls.

Worked example: a device loaned for one specialist patient

A community service borrows a specialist monitoring device for a named patient. The clinical lead confirms the device is suitable for the patient’s care plan and home environment. The agreement identifies who provides batteries, sensors, servicing and out-of-hours fault support. A competent person checks function and configuration before deployment. The patient and carers receive instructions on operation, alarms, cleaning and whom to call if the device fails. The service records the device serial number and location in a controlled system without copying unnecessary patient details into the general asset register.

When the patient’s need changes, the service retrieves the device, follows the manufacturer’s decontamination instructions and records its condition. It does not hand the unit to a second patient immediately. If a safety notice arrives later, the service can establish who held the device and when. This example shows why a small loan can create a substantial clinical and traceability task even when no purchase order exists.

FAQs

Sources

• MHRA: Managing Medical Devices
• MHRA: Managing Medical Devices full guidance
• GOV.UK: Health and Social Care Act 2008 code of practice on infection prevention
• MHRA: safety communications and field safety notices
• Complys: hospitals page

Related: hospitals compliance software, health surveillance software, and more compliance guides.